Product information and disease descriptionPlace of product in therapyApproaches to treatment
Expected outcomes of therapy
11 evidence topics · 15 sources
Summary: symptom change, response, and remission
In the phase 3 trials, which compared a single dose of DT120 ODT 100 µg with placebo and have reported company topline results, the LS mean HAM-A total score decreased by 11.6 points (Voyage) and 9.8 points (Panorama) at Week 12, compared with 6.2 and 4.7 points with placebo. The placebo-adjusted differences of 5.4 and 5.1 points compare with a minimal clinically important difference of 2.5 points used in the phase 2b trial. At Week 12, 43% (Voyage) and 32% (Panorama) of participants given DT120 had a response (HAM-A improvement of 50% or more) and 14% and 15% a remission (HAM-A of 7 or less), compared with 16% and 14% (response) and 4% and 4% (remission) with placebo. In the phase 2b trial, which used capsules, response at Week 12 occurred in 26 of 40 participants (65.0%) given 100 µg and 12 of 39 (30.8%) given placebo, and remission in 19 (47.5%) and 8 (20.5%).
Summary: onset, durability, and the dosing session
Differences from placebo were present early: CGI-S change at Day 2 differed by -0.8 in both phase 3 trials, and HAM-A change at Week 1 by -7.7 (Voyage) and -5.3 (Panorama) points. The controlled comparison covers 12 weeks after one dose. In the 40-week extensions participants could receive open-label DT120 ODT (in Voyage, up to four additional doses based on symptom severity); in interim analyses of partial data (cutoffs July 15, 2026 and August 11, 2026), 60% of 37 Voyage participants and 48% of 27 Panorama participants given DT120 in Part A had a HAM-A response at Week 28. FDA guidance asks sponsors to follow participants beyond Week 12 for symptom recurrence or a need for repeat dosing. Transient perceptual, affective, and emotional effects occurred primarily on the dosing day. Participants were observed by dosing session monitors for at least 8 hours and until they cleared an end-of-session checklist; mean time to clearance was 6.4 hours in Voyage and 6.2 hours in Panorama, and by hour 8, 92% (topline announcement) or 90% (poster) of Voyage participants, 94% of Panorama participants, and 97% across more than 1,000 phase 3 sessions through September 10, 2026 had cleared it. The sponsor states that normal activities, including driving, resume the next day.
Definitions of response and remission in anxiety disorders
“Response is generally regarded as a clinically meaningful improvement in symptoms, while remission, the goal of treatment, is generally thought of as the absence or near absence of symptoms following illness, accompanied by a return to premorbid levels of functioning.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“While no universally accepted criteria exist, a commonly used threshold for response is a >50% improvement in the total score, while for remission, various cutoff points have been used.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
HAM-A severity bands and minimal clinically important difference
“score range, 0-56; higher scores indicate greater severity; ≤7 indicates no or minimal anxiety; 8-14, mild; 15-23, moderate; and ≥24, severe” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“The minimal clinically important difference was 2.5 points.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Expected HAM-A differences from placebo with existing drugs: network meta-analysis
“This analysis is based on 89 trials, which included 25 441 patients randomly assigned to 22 different active drugs or placebo.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“Duloxetine (MD -3·13, 95% credible interval [CrI] -4·13 to -2·13), pregabalin (MD -2·79, 95% CrI -3·69 to -1·91), venlafaxine (MD -2·69, 95% CrI -3·50 to -1·89), and escitalopram (MD -2·45, 95% CrI -3·27 to -1·63) were more efficacious than placebo with relatively good acceptability.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“Quetiapine (MD -3·60 95% CrI -4·83 to -2·39) had the largest effect on HAM-A but it was poorly tolerated (odds ratio 1·44, 95% CrI 1·16-1·80) when compared with placebo.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
Pooled effect sizes of psychotherapy and medication
“Psychotherapy showed a medium to large effect size (g = 0.76) and medication showed a small effect size (g = 0.38) on GAD outcomes.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Because medication studies had more placebo control conditions than inactive conditions compared to psychotherapy studies, effect sizes between the domains should not be compared directly.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
DT120 in Voyage: response and remission at Week 12
| Outcome at Week 12 | DT120 ODT | Placebo ODT | Placebo-adjusted difference |
|---|---|---|---|
| HAM-A response rate (≥50%) | “43%” | “16%” | “27% (p<0.0001)” |
| HAM-A remission rate (≤7) | “14%” | “4%” | “10% (p=0.0222)” |
DT120 in Panorama: response and remission at Week 12
| Outcome at Week 12 | DT120 ODT 100 µg | Placebo ODT | Placebo-adjusted difference |
|---|---|---|---|
| HAM-A response rate (≥50%) | “32%” | “14%” | “18% (p<0.05)” |
| HAM-A remission rate (≤7) | “15%” | “4%” | “12% (p<0.05)” |